Check out our latest blog post for our breakdown on what makes GLP-1s unique, what to watch for in the upcoming model, and why this matters for manufacturers, payers, and policymakers alike: #CMMI #Pharmaceuticals #HealthPolicy #GLP1 #DrugPricing To view or add a comment, sign in More Relevant Posts GLP-1 therapies are transforming care and sparking major policy questions
Esta limitacin reduce el inters de la industria farmacutica en invertir en investigaciones costosas, como los estudios clnicos en fases I, II y III, necesarios para su aprobacin regulatoria
By understanding the science and respecting the timing, you put yourself in the best possible position to observe the true effects of these fascinating compounds
David Smith, urologist and co-founder of medical device company BladGo Medical, told Drugwatch
That means deficiencies get caught earlier, and doctors are more willing to prescribe an injectable course when levels are seriously low
Arthritis Individuals with HS are three times more likely to develop inflammatory arthritis, which is a group of chronic autoimmune disorders